Sign In
Buy ESPR
$3.14
+0 (+0%)
At Close: Jun 03, 2026
– Bempedoic Acid Lowered LDL-C and Was Well Tolerated in Children Aged 6-17 Years – – A Secondary Analysis of CLEAR Outcomes Reports on Patient Factors Associated With 30% or Greater Reduction i
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
04:30pm, Thursday, 14'th May 2026
ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperio
ESPR Stock Surges 44% in a Month: Here's What You Need to Know
11:46am, Thursday, 14'th May 2026
Esperion shares jump nearly 44% in a month. The primary catalyst was Archimed's agreement to acquire the company in a deal valued at up to $1.1 billion, including milestone payments.
– Presentations Examine Findings From the Pediatric Phase 2 Study, As Well As Factors Associated With Enhanced LDL-C Reductions in Adult Patients Enrolled in Clear Outcomes – – Pediatric Phase
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—PFLC, ESPR, LKSB, and MKC
01:15pm, Tuesday, 05'th May 2026
NEW YORK, May 05, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Esperion Therapeutics, Inc. (NASDAQ: ESPR)
12:55pm, Friday, 01'st May 2026
NEW YORK, May 01, 2026 (GLOBE NEWSWIRE) -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders a
Shareholder Alert: Ademi LLP investigates whether Esperion Therapeutics, Inc. is obtaining a Fair Price for Public Shareholders
11:30am, Friday, 01'st May 2026
MILWAUKEE, May 1, 2026 /PRNewswire/ -- Ademi LLP is investigating Esperion (NASDAQ: ESPR) for possible breaches of fiduciary duty and other violations of law in its recently announced transaction with
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Esperion Therapeutics, Inc. (NASDAQ: ESPR) to funds managed by ARCHIMED for $3.16 per share in ca
Archimed to take Esperion Therapeutics private in $1.1 billion deal
07:37am, Friday, 01'st May 2026
Investment firm Archimed will take Esperion Therapeutics private for up to $1.1 billion, the companies said on Friday, sending the drugmaker's shares up over 55% in premarket trading.
Esperion to be Acquired by ARCHIMED
07:00am, Friday, 01'st May 2026
Esperion shareholders to receive $3.16 per share in cash at closing, plus the right to participate in up to $100 million in aggregate contingent milestone payments
Esperion to Report First Quarter 2026 Financial Results on May 7
08:00am, Thursday, 23'rd Apr 2026
ANN ARBOR, Mich., April 23, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2026 financial results before the market opens on Thursday, May 7, 2026.
Esperion Therapeutics Highlights 38% Revenue Growth, Enbumyst Launch Plan at Needham Conference
03:35am, Wednesday, 15'th Apr 2026
Esperion Therapeutics (NASDAQ: ESPR) outlined its commercial progress and strategic priorities at Needham and Company's 25th Annual Healthcare Conference, highlighting revenue growth, new clinical and
Esperion Therapeutics (ESPR) Down 10% Since Last Earnings Report: Can It Rebound?
12:31pm, Thursday, 09'th Apr 2026
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock?
Esperion Therapeutics, Inc. $ESPR Shares Purchased by JPMorgan Chase & Co.
04:59am, Monday, 06'th Apr 2026
JPMorgan Chase and Co. raised its stake in Esperion Therapeutics, Inc. (NASDAQ: ESPR) by 68.4% in the third quarter, according to the company in its most recent disclosure with the Securities and Exch
